![SonomaEye-full-color-vector[2].png](https://static.wixstatic.com/media/bed00b_da20b9cc704044b0b048ac8ef9190470~mv2_d_3024_2195_s_2.png/v1/fill/w_177,h_122,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/SonomaEye-full-color-vector%5B2%5D.png)
Correlation between Atrophy Size on Fundus Autofluorescence and Ellipsoid Zone Defect area on OCT Measurements of Geographic Atrophy
Presenter:
Amir Hariri
Authors:
Amir Hariri, MD, Mohamed Ahmed, MD, Rubbia Afridi, MD, Yasir Sepah, MD, Quan Dong Nguyen, MD
1. OIRRC
2. Byers Eye Institute
Affiliation:
Purpose: To evaluate correlation between atrophy size on fundus autofluorescence and ellipsoid zone defect area on OCT measurements of geographic atrophy
Design: Retrospective, cross-sectional study
Participants: Four hundred twenty eyes from 230 subjects with GA associated with age-related macular degeneration.
Methods: Subjects with atrophic age-related macular degeneration who underwent both FAF and SD-OCT (Heidelberg)imaging were included in this retrospective analysis. The borders of all areas of definite decreased autofluorescence (DDAF) corresponding to GA were semi-automatically outlined on FAF images by certified graders at OIRRC using region finder tool. EZ defect was manually delineated on every single b-scan on OCT and a custom-made software generated EZ defect map by interpolating between adjacent b-scans. The fundus autofluorescence and SD-OCT-derived measurements were correlated.
Main Outcome Measures: Correlation between EZ defect and DDAF area measurements.
Results: The mean GA area measured from the FAF images was 4.75 ± 3.44 mm2, compared with an EZ defect area of 4.94 ±3.45 mm2 measured using SD-OCT. There was a significant correlation between these two measurements (r = 0.97; P < 0.001).
Conclusions: Spectral-domain OCT-derived measurements of EZ defect area correlates well with areas of DDAF obtainedfrom FAF images. This observation may support the use of SD-OCT-based measurements of the EZ defect area as a surrogate outcome measure in clinical research and clinical trials